多实践场景下经皮深静脉动脉化结局的比较
回顾性比较医院与办公室实验室(OBL)场景下经皮深静脉动脉化(pDVA)治疗无选择慢性肢体威胁性缺血的结局。纳入73例患者(医院41例,OBL 32例),主要终点为主要无截肢生存(AFS),两组在主要AFS、保肢、生存、一期通畅率及伤口愈合方面均无显著差异。
要点
- 医院组与OBL组主要AFS、保肢、生存、一期通畅率及部分/完全伤口愈合均无显著差异。
- OBL组再干预率高于医院组(45.2% vs 20.5%)。
- pDVA在医院和OBL场景下治疗无选择慢性肢体威胁性缺血均可行且安全。
核心结论
- pDVA在医院和OBL场景下治疗无选择慢性肢体威胁性缺血均可行且安全,≤2年结局无显著差异。
研究设计与样本
- 回顾性病历审查,纳入2018年1月至2023年3月在医院和OBL使用现成器械接受pDVA的患者,共73例(医院41例,OBL 32例)。
- 医院组59%男性,中位年龄72岁(四分位距18年);OBL组59%男性,年龄67岁(四分位距16年)。
- 纳入标准为无选择严重肢体缺血、至少一条通畅的近端胫动脉可用于建立动静脉吻合、Rutherford IV级或以上外周动脉疾病。
- 排除标准为Rutherford III级或以下、活动性感染、无至少一个合适静脉靶点、和/或需要立即大截肢的快速进展伤口。
主要发现
- 技术成功70例(96%),医院组1例(2.4%)、OBL组2例(6.3%)失访。
- 6个月、1年、2年主要AFS估计值:医院组分别为51.4%、40.4%、30.2%,OBL组分别为69.4%、54.0%、49.5%。
- 6个月、1年、2年部分伤口愈合估计值:医院组分别为27.5%、71.7%、81.2%,OBL组各时间点均为62.7%。
- 6个月、1年、2年完全伤口愈合估计值:医院组分别为6.7%、33.3%、33.3%,OBL组分别为5.3%、37.7%、41.6%。
- 主要AFS(P = .13)、保肢(P = .07)、生存(P = .69)、一期通畅率(P = .53)、部分(P = .08)及完全伤口愈合(P = .79)组间均无显著差异;再干预医院组8例(20.5%)、OBL组14例(45.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We compared the efficacy of percutaneous deep venous arterialization (pDVA) in patients with no-option chronic limb-threatening ischemia in the hospital vs in office-based laboratory (OBL) settings. METHODS: A retrospective chart review was performed of all patients who underwent pDVA using off-the-shelf devices from January 2018 to March 2023 in a hospital and an OBL. We identified 73 eligible patients, 41 from a hospital setting (59% male; median age, 72 years; interquartile range, 18 years) and 32 from an OBL setting (59% males; 67 years; interquartile range, 16 years). All eligible patients were deemed to have no-option critical limb ischemia, had at least one patent proximal tibial artery available for the creation of an arteriovenous anastomosis, and were classified as having Rutherford classification IV or higher peripheral arterial disease. Patients were ineligible if classified as Rutherford classification III or lower, had active infection, did not have at least one appropriate venous target, and/or had rapidly progressing wounds requiring immediate major amputation. The primary outcome was major amputation-free survival (AFS). Secondary outcomes included technical success, limb salvage, survival, primary patency, reintervention rate, adverse events, and partial and complete wound healing. Outcomes were evaluated using Kaplan-Meier method, log-rank, and two-stage procedure tests. RESULTS: Technical success was achieved in 70 patients (96%) with 1 hospital (2.4%) and 2 OBL (6.3%) patients lost to follow-up. Major AFS estimates at 6 months, 1 year, and 2 years were 51.4%, 40.4%, and 30.2% in the hospital group and 69.4%, 54.0%, and 49.5% in the OBL group, respectively. Partial wound healing estimates at 6 months, 1 year, and 2 years were 27.5%, 71.7%, and 81.2% in the hospital group and 62.7% at all time points in the OBL group. Complete wound healing estimates at 6 months, 1 year, and 2 years were 6.7%, 33.3%, and 33.3% in the hospital group and 5.3%, 37.7%, and 41.6% in the OBL group, respectively. There was no significant difference in major AFS (P = .13), limb salvage (P = .07), survival (P = .69), primary patency (P = .53), partial (P = .08), or complete wound healing (P = .79) between groups. Reintervention was performed in 8 hospital (20.5%) and 14 OBL (45.2%) patients. CONCLUSIONS: pDVA is a feasible and safe procedure for no-option critical limb ischemia in the hospital and OBL setting without significant differences in outcomes at ≤2 years.
引用
- Saini N, Marrone L, Desai S, et al. Comparison of outcomes of percutaneous deep venous arterialization in multiple practice settings. J Vasc Surg. 2024. PMID: 38830436. doi:10.1016/j.jvs.2024.05.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。